Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, made an important announcement today that the first patient has been admitted in the Phase 2a clinical study. This study will be pivotal iin evaluating AV-001 in hospitalized patients experiencing severe symptoms COVID-19 disease.
Vasomune Therapeutics, Inc.
GET A FREE STOCK REPORT
Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.
Recent Articles
Cryptocurrency
What’s the buzz about Bone ShibaSwap (BONE) crypto?
- May 26, 2022 03:22 PM AEST
- Team Kalkine Media
Economy
Aussie petrol prices set for record highs: Factors fuelling rise
- May 26, 2022 03:18 PM AEST
- Toshiva Jain
Stock Market
IFT, MCY, GNE: How did these 3 ASX renewable energy stocks fare YTD?
- May 26, 2022 03:13 PM AEST
- Bhawna Gupta
.png "Jack Dorsey to never return to Twitter | Trending News Australia")
.png "Which ASX Penny Stocks trended on May 25?")
.png "What is fuelling petrol price rise in Australia? | Trending News Australia")
.png "What’s Driving 30% Rally In Appen (ASX:APX) Share Price?")
.png "DFI.Money (YFII) Crypto Trading Volume Skyrocketed By Over 2798%")
.png "Why is MMORPG Outer Ring (GQ) Crypto Gaining Attention?")
Be the First to Comment